We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Animal Testing can Mislead Drug Discovery and Development

Animal Testing can Mislead Drug Discovery and Development

Animal Testing can Mislead Drug Discovery and Development

Animal Testing can Mislead Drug Discovery and Development

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Animal Testing can Mislead Drug Discovery and Development"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The research, carried out by PharmaInformatic, a German biotech company, compared study results on drug-uptake (“Oral Bioavailability”) in animals and humans for a large number of approved and established drugs.

Results showed that oral bioavailability in animals is inconsistent with the values reported for humans and large differences can exist. This also applies to very successful commercial drugs, called blockbuster drugs, with annual sales of more than one billion US Dollar.

In drug development, a large number of compounds are tested in animals, such as rats, dogs, monkeys and mice to determine whether they are effective and possess sufficient oral bioavailability. If bioavailability in animals is too low, further drug development is usually discontinued.

Drug-uptake studies in animals can be misleading: Aripiprazole and Esomeprazole, the most sold drugs of 2013, have low oral bioavailability in animals, but drug-uptake in humans is high.

Alternative computational methods, such as the expert system IMPACT-F replace animal trials on drug-uptake.

Pharmaceutical companies have applied the expert system to evaluate human oral bioavailability in various therapeutic areas such as diabetes, inflammation, antivirals, autoimmune diseases and cancer.

The expert system evaluates oral bioavailability in humans significantly more reliably than animal trials. This further increases the prospects of human clinical trials, because the optimum oral dose for first-in-human clinical trials can be determined much more accurately. Efficacy issues are identified as the main reason why clinical trials fail.